Payment overview · 2025
General Payments
$1,243.50
46 reported records · 13 companies
Healthcare provider profile · identity verified
Derek Nguyen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RIVERSIDE, CA · NPI 1528054095
Verified facts
What the public records show
CMS Open Payments records show Derek Nguyen, MD received $1,243.50 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $492.56 | 39.6% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.67 | 13.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $133.09 | 10.7% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$72.95 | 5.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.54 | 5.3% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $52.87 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.54 | 3.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $44.25 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.95 | 3.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.61 | 3.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.11 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.04 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.32 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,243.50 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $264.75 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $249.85 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $210.40 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.67 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $133.09 | 6 | 2025 |
Source payment records
|
|||||
| CATALYFT PL EXPANDABLE INTERBODY SYSTEM Normalized: catalyft pl expandable interbody system |
Device | Medtronic, Inc. | $72.95 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $66.54 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $52.87 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $44.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.95 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.61 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.11 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1141 | 296 |
| Amlodipine Besylate | Amlodipine Besylate | 628 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 144 |
| Lisinopril | Lisinopril | 483 | 133 |
| Metformin Hcl | Metformin Hcl | 456 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 399 | 125 |
| Eliquis | Apixaban | 350 | 80 |
| Gabapentin | Gabapentin | 348 | 92 |
| Furosemide | Furosemide | 338 | 94 |
| Losartan Potassium | Losartan Potassium | 329 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 326 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 296 | 74 |
| Potassium Chloride | Potassium Chloride | 229 | 64 |
| Famotidine | Famotidine | 224 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 66 |
| Carvedilol | Carvedilol | 203 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 203 | 40 |
| Divalproex Sodium | Divalproex Sodium | 189 | 34 |
| Omeprazole | Omeprazole | 187 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 48 |
| Trazodone Hcl | Trazodone Hcl | 171 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 57 |
| Ozempic | Semaglutide | 155 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 153 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 144 | 31 |
| Sertraline Hcl | Sertraline Hcl | 143 | 22 |
| Alendronate Sodium | Alendronate Sodium | 140 | 38 |
| Alprazolam | Alprazolam | 140 | 33 |
| Azithromycin | Azithromycin | 140 | 99 |
| Mirtazapine | Mirtazapine | 140 | 34 |
| Montelukast Sodium | Montelukast Sodium | 138 | 48 |
| Levetiracetam | Levetiracetam | 135 | 21 |
| Tramadol Hcl | Tramadol Hcl | 135 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 49 |
| Donepezil Hcl | Donepezil Hcl | 125 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 31 |
| Simvastatin | Simvastatin | 112 | 30 |
| Allopurinol | Allopurinol | 97 | 25 |
| Lidocaine | Lidocaine | 97 | 23 |
| Farxiga | Dapagliflozin Propanediol | 90 | 24 |
| Lorazepam | Lorazepam | 87 | 37 |
| Prednisone | Prednisone | 87 | 60 |
| Benazepril Hcl | Benazepril Hcl | 85 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 23 |
| Xarelto | Rivaroxaban | 84 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 44 |
| Sodium Chloride | 0.9 % Sodium Chloride | 83 | 25 |
| Meloxicam | Meloxicam | 79 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 33 |
| Metformin Hcl Er | Metformin Hcl | 77 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 52 |
| Finasteride | Finasteride | 75 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 57 |
| Risperidone | Risperidone | 70 | 15 |
| Spironolactone | Spironolactone | 68 | 23 |
| Cephalexin | Cephalexin | 67 | 50 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 24 |
| Ezetimibe | Ezetimibe | 65 | 17 |
| Olanzapine | Olanzapine | 61 | 17 |
| Labetalol Hcl | Labetalol Hcl | 60 | 20 |
| Meclizine Hcl | Meclizine Hcl | 60 | 20 |
| Memantine Hcl | Memantine Hcl | 59 | 18 |
| Methocarbamol | Methocarbamol | 58 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 57 | 23 |
| Celecoxib | Celecoxib | 57 | 14 |
| Nifedipine Er | Nifedipine | 56 | 17 |
| Buspirone Hcl | Buspirone Hcl | 53 | 12 |
| Ertapenem | Ertapenem Sodium | 53 | 17 |
| Linzess | Linaclotide | 52 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 35 |
| Atenolol | Atenolol | 50 | 18 |
| Ibuprofen | Ibuprofen | 50 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 26 |
| Clozapine | Clozapine | 49 | suppressed |
| Nystatin | Nystatin | 48 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 13 |
| Azelastine Hcl | Azelastine Hcl | 47 | 19 |
| Ondansetron Odt | Ondansetron | 47 | 21 |
| Primidone | Primidone | 46 | suppressed |
| Humalog | Insulin Lispro | 45 | 20 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Cefdinir | Cefdinir | 44 | 34 |
| Lacosamide | Lacosamide | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 43 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 15 |
| Mupirocin | Mupirocin | 42 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 12 |
| Entresto | Sacubitril/Valsartan | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Glipizide | Glipizide | 41 | suppressed |
| Latanoprost | Latanoprost | 41 | 11 |
| Valsartan | Valsartan | 40 | 15 |
| Sucralfate | Sucralfate | 39 | 14 |
| Ketoconazole | Ketoconazole | 38 | 20 |
| Megestrol Acetate | Megestrol Acetate | 38 | 16 |
| Ssd | Silver Sulfadiazine | 38 | 17 |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 37 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Baclofen | Baclofen | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 18 |
| Midodrine Hcl | Midodrine Hcl | 34 | 11 |
| Pregabalin | Pregabalin | 34 | 11 |
| Sevelamer Hcl | Sevelamer Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 16 |
| Naproxen | Naproxen | 33 | 14 |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 19 |
| Fluconazole | Fluconazole | 31 | 24 |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Heparin Sodium | Heparin Sodium,porcine | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 29 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 28 | 15 |
| Lactulose | Lactulose | 27 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 24 |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 14 |
| Gemtesa | Vibegron | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Morphine Sulfate | Morphine Sulfate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Betamethasone Valerate | Betamethasone Valerate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 20 | 14 |
| Ursodiol | Ursodiol | 20 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Admelog | Insulin Lispro | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Isoniazid | Isoniazid | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,243.50 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, CATALYFT PL EXPANDABLE INTERBODY SYSTEM, Cologuard Collection Kit, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, NUZYRA, Ozempic, REXULTI, XHANCE, XIFAXAN, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error